ISA Pharmaceuticals’ ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab

Towards a Best Practice Approach in Cancer Immunotherapy: Cancer Vaccines Gain Momentum

ISA Pharmaceuticals Further Strengthens IP Position on Lead Compound ISA101

New Peer-Reviewed Publication Provides Further Insights into Mechanism of ISA Pharmaceuticals’ SLP® Immunotherapeutics

ISA Pharmaceuticals Granted European Patent for the Intradermal Administration of ISA101

ISA Pharmaceuticals signs R&D agreement with Shin Nippon Biomedical Laboratories

ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugates